This CPB has been revised to state that (i) plasmapheresis, plasma exchange, or therapeutic apheresis is considered medically necessary for acute, severe neurological deficits caused by multiple sclerosis that have a poor response to treatment with high-dose glucocorticoids, and (ii) plasmapheresis/plasma exchange is considered experimental and investigational for optic neuritis.